Los ganglios basales: la participación dopaminérgica estriatal
Palabras clave:
Dopamina, neoestriado, receptor D1, receptor D2, liberación de dopamina, ganglios basalesResumen
Los ganglios basales (GB) están asociados a las funciones motoras y no motoras. El neoestriado
forma parte de los GB y su función es críticamente modulada por la dopamina a través de la
activación de receptores D1 y D2 postsinápticos expresados en las neuronas espinosas de tamaño
mediano y que median la vía directa estriadonigral e indirecta estriadopalidal, respectivamente.
La liberación de dopamina estriatal, modulada por la administración de agonistas y antago-
nistas dopaminérgicos, es explicada a través del sistema de retroalimentación negativa, que
involucra receptores pre- y postsinápticos. El estudio del sistema dopaminérgico estriatal puede
contribuir al entendimiento en la fisiología y disfunción de los GB. La presente revisión tiene el
propósito de explicar la participación dopaminérgica estriatal en los GB y la función motora.
##plugins.generic.pfl.publicationFactsTitle##
##plugins.generic.pfl.reviewerProfiles## N/D
##plugins.generic.pfl.authorStatements##
Indexado: {$indexList}
-
##plugins.generic.pfl.indexedList##
- ##plugins.generic.pfl.editorAndBoard##
- ##plugins.generic.pfl.profiles##
- ##plugins.generic.pfl.academicSociety##
- N/D
Para obtener más información sobre un dato, haga clic
##plugins.generic.pfl.maintainedByPKP##
Citas
Bolam JP, Hanley JJ, Booth PA, Bevan MD. Synaptic
organization of the basal ganglia. J Anat. 2000; 196:
-542.
Jaeger D, Kita H. Functional connectivity and integrative
properties of globus pallidus neurons. Neuroscience.
; 198: 44-53.
Kandel ER, Schwartz JH, Jessell TM, Siegelbaum SA,
Hudspeth AJ. Principles of Neural Science. 5th ed. New
York: McGraw-Hill; 2013.
Hamani C, Saint-Cyr JA, Fraser J, Kaplitt M, Lozano AM.
The subthalamic nucleus in the context of movement
disorders. Brain. 2004; 127: 4-20.
Zhou FM, Lee CR. Intrinsic and integrative properties of
substantia nigra pars reticulata neurons. Neuroscience.
; 15 (198): 69-94.
Groenewegen HJ. The basal ganglia and motor control.
Neural Plast. 2003; 10: 107-120.
Kreitzer AC, Malenka RC. Striatal plasticity and basal
ganglia circuit function. Neuron Rev. 2008; 60: 543-554.
Surmeier DJ, Ding J, Day M, Wang Z, Shen W. D1 and
D2 dopamine-receptor modulation of striatal glutamater-
gic signaling in striatal medium spiny neurons. Trends
Neurosci. 2007; 30: 228-235.
Wilson CJ, Kawaguchi Y. The origins of two-state spon-
taneous membrane potential fl uctuations of neostriatal
spiny neurons. J Neurosci. 1996; 16: 2397-2410.
Palermo-Neto J. Dopaminergic systems. Dopamine
receptors. Psychiatr Clin North Am. 1997; 20: 705-721.
Jackson DM, Westlind-Danielsson A. Dopamine recep-
tors: molecular biology, biochemistry and behavioural
aspects. Pharmacol Therapeut. 1994; 64: 291-370.
Saklayen SS, Mabrouk OS, Pehek EA. Negative feed-
back regulation of nigrostriatal dopamine release: me-
diation by striatal D1 receptors. J Pharmacol Exp Ther.
; 311: 342-348.
Wolf ME, Deutch AY, Roth RH. Pharmacology of central
dopaminergic neurons. En: Henn FA, DeLisi LE, Eds.
Handbook of Schizophrenia, Vol. 2: Neurochemistry
and Neuropharmacology of Schizophrenia. New York:
Elsevier; 1987. pp. 101-147.
Abraini JH, Fechtali T, Rostain JC. Lasting effects of
dopamine receptor agonists upon striatal dopamine
release in free-moving rats: an in vivo voltammetric
study. Brain Res. 1994; 642: 199-205.
Imperato A, Mulas A, Di Chiara G. The D-1 antagonist
SCH23390 stimulates while the D-1 agonist SKF38393
fails to affect dopamine release in the dorsal caudate
of freely moving rats. Eur J Pharmacol. 1987; 142:
-181.
Imperato A, Di Chiara G. Effects of locally applied D-1
and D-2 receptor agonists and antagonists studied with
brain dialysis. Eur J Pharmacol. 1988; 156: 385-393.
Zackheim JA, Abercrombie ED. Decreased striatal
dopamine effl ux after intrastriatal application of benzaz-
epine-class D1 agonists is not mediated via dopamine
receptors. Brain Res. Bull. 2001; 54: 603-607.
Bueno-Nava A, Gonzalez-Pina R, Alfaro-Rodriguez A,
Avila-Luna A, Arch-Tirado E, Alonso-Spilsbury M. The
selective inhibition of the D1 dopamine receptor results
in an increase of metabolized dopamine in the rat stria-
tum. Neurochem Res. 2012; 37: 1783-1789.
Westerink BH, Vries JB. On the mechanism of neuro-
leptic induced increase in striatal dopamine release:
brain dialysis provides direct evidence for mediation by
autoreceptors localized on nerve terminals. Neurosci
Lett. 1989; 99: 197-202.
Sotnikova T, Gainetdinov RR, Grekhova TV, Rayevsky
KS. Effects of intrastriatal infusion of D2 and D3 dopa-
mine receptor preferring antagonists on dopamine re-
lease in rat dorsal striatum (in vivo microdialysis study).
Pharmacol Res. 2001; 43: 283-290.
Burkhardt JM, Jin X, Costa RM. Dissociable effects of
dopamine on neuronal fi ring rate and synchrony in the
dorsal striatum. Front Integr Neurosci. 2009; 3: 28.
Sokoloff P, Leriche L, Le Foll B. Dopamine receptors.
Structure, function and implication in psychiatric disor-
ders. In: Gorwood P, Hamon M, ed. Psychopharmacoge-
netics. New York, NY, USA: Springer Science+Business
Media, Inc.; 2006. pp. 357-419.
Martín AB, Fernandez-Espejo E, Ferrer B, Gorriti MG,
Bilbao A, Navarro M et al. Expression and function of CB1
receptor in the rat striatum: localization and effects on D1
and D2 dopamine receptor-mediated motor behaviors.
Neuropsychopharmacology. 2008; 33: 1667-1679.
Hiroi N, Martín AB, Grande C, Alberti I, Rivera A, Mo-
ratalla R. Molecular dissection of dopamine receptor
signaling. J Chem Neuroanat. 2002; 23: 237-242.
Darmopil S, Martín AB, De Diego IR, Ares S, Moratalla
R. Genetic inactivation of dopamine D1 but not D2 re-
ceptors inhibits L-DOPA-induced dyskinesia and histone
activation. Biol Psychiatry. 2009; 66: 603-613.
Xu M, Koeltzow TE, Santiago GT, Moratalla R, Cooper
DC, Hu X-T, et al. Dopamine D3 receptor mutant mice
exhibit increased behavioral sensitivity to concurrent
stimulation of D1 and D2 receptors. Neuron. 1997; 19:
-848.
Elizabeth A. Sabens, Kelly M. Steller, John J. Mieyal
Levodopa activates apoptosis signaling kinase 1 (ASK1)
and promotes apoptosis in a neuronal model: implica-
tions for the treatment of Parkinson’s Disease. Chem
Res Toxicol. 2011; 24 (10): 1644-1652.
Nestler EJ, Hyman SE, Malenka RC. Molecular neuro-
pharmacology. 2a ed. McGraw-Hill, New York; 2009.
Mark K. Lyons mayo. Deep brain stimulation: current
and future clinical applications. Clin Proc. 2011; 86 (7):
-672.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2026 Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
© Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra under a Creative Commons Attribution 4.0 International (CC BY 4.0) license which allows to reproduce and modify the content if appropiate recognition to the original source is given.
